Southpoint Capital Advisors LP sold $636k of FENC
owner at FENNEC PHARMACEUTICALS INC.. 67,114 shares at an average of $9.48, traded Oct 7, 2025, filed Oct 9, 2025.
Score components
- +12Role10% owner
- +20Trade size$636k at market
- 0Share of holdings soldSold 1.6% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -14.5%, 3m -18.8%, 6m -31.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001012975-25-000621, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 7, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -26,900 | $9.59 | $258k | 4,050,314 | Oct 9, 2025 |
| Oct 8, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -19,605 | $9.47 | $186k | 4,030,709 | Oct 9, 2025 |
| Oct 9, 2025 | SOpen-market sale Common Stockindirect: See Footnote | -20,609 | $9.35 | $193k | 4,010,100 | Oct 9, 2025 |
Related signals
Other insiders at FENNEC PHARMACEUTICALS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | FENNEC PHARMACEUTICALS INC. | Marco Maria Brughera director | $160k 15,545 shares | -100% | |
| 13Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $121k 10,000 shares | -7% | |
| 61Notable | FENNEC PHARMACEUTICALS INC. | Pierre Sargis Sayad Chief Medical Officer | $146k 12,000 shares | -56% | |
| 35Weak | FENNEC PHARMACEUTICALS INC. | Robert Andrade CHIEF FINANCIAL OFFICER | $884k 75,000 shares | -26% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $96k 10,000 shares | -7% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $100k 9,599 shares | -6% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $94k 9,747 shares | -7% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Chris A Rallis director | $59k 8,346 shares | -12% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $70k 10,781 shares | -8% | |
| 0Weak | FENNEC PHARMACEUTICALS INC. | Rosty Raykov CHIEF EXECUTIVE OFFICER | $69k 10,946 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.